Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Old API Wind-down Ltd - Ordinary Shares
ARLZQ
Healthcare
Drug Manufacturers - Major
Drug Manufacturers - Specialty & Generic
"Old API Wind-down Ltd, formerly Aralez Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the acquisition, development, and commercialization of products primarily in cardiovascular, pain management and other specialty areas. Its key products include Fiorinal, Proferrin, Fibricor, Uracyst and Neovisc, Cambia and other marketed products. The company currently...
operates in two geographical markets, the United States and Canada. The firm generates most of its reven
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (OTCPK:ARLZQ)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(61)
•••
snootchybootchy
X
View Profile
View Bullboard History
Comment by
snootchybootchy
on Mar 27, 2017 5:39pm
RE:RE:Another Seeking Alpha article
Yes, a flop in Zontivity would change the story in my mind, because that would also likely affect Yosprala sales. But again, if uptake of Zontivity is slow a few months after the launch, I would
...more
(0)
•••
GoldenDilemma
X
View Profile
View Bullboard History
Comment by
GoldenDilemma
on Mar 27, 2017 3:01pm
RE:Another Seeking Alpha article
When does the story change in your mind? A Zontivity flop? Lackluster Yosprala sales? And, to add, post earnings drop is a micro perspective ignoring the macro perspective of the downward slope
...more
Lahontan Completes Phase Two of 2024 Drilling at Santa Fe
posted Jun 25, 2024 9:00am by
Lahontan Gold Corp.
-
|
"Lahontan is excited to complete the second Phase of our 2024 drilling campaign at Santa Fe. The drilling was completed rapidly and under budget, a tribute to our geologic team and the excellent drill crew. Work on the PEA continues at an accelerating pace, with site visits, scoping studies on capex and operating costs underway. We will continue to update investors as the PEA progresses and when assay results from the 2024 drilling program are received". ...read more
(61)
•••
snootchybootchy
X
View Profile
View Bullboard History
Post by
snootchybootchy
on Mar 27, 2017 2:39pm
Another Seeking Alpha article
Mr. Goldman has been busy working on this T.ARZ. The new article summarizes his interview with Mr. Adams and he also provides some updated thoughts on the prospects of Aralez going forward
...more
(0)
•••
kuatolives
X
View Profile
View Bullboard History
Comment by
kuatolives
on Mar 26, 2017 12:34pm
RE:Interview with Adrian Adams
Don't listen to this dog and pony show. After wiping out Tribute shareholders, Mr. Goldman sold half his stake in Aralez just recently, so his actions don't reflect the 'confidence' he
...more
(61)
•••
snootchybootchy
X
View Profile
View Bullboard History
Post by
snootchybootchy
on Mar 25, 2017 3:45pm
Interview with Adrian Adams
There is an interview with Mr. Adams posted up on Seeking Alpha. One can see why Mr. Adams is still optimistic -- he thinks there is lots of potential with Zontivity and he also believes that
...more
(15)
•••
Systemtogo
X
View Profile
View Bullboard History
Comment by
Systemtogo
on Mar 22, 2017 11:00pm
RE:RE:PPI May Cause Kidney Damage
I know people that have been on ppi's for many years and don't have kidney issues. If you have serious gastritis and GERD then you need them. Two in one, Naproxen with PPI's are a common
...more
(28)
•••
CHECKMATE77
X
View Profile
View Bullboard History
Comment by
CHECKMATE77
on Mar 22, 2017 4:28pm
RE:PPI May Cause Kidney Damage
i am in healthcare, ppi have a number of issues not just the above but they also 1- prevent to a degree gastric perferation 2- improve quality of life hell asa has issues...name a drug that does not
...more
(0)
•••
kuatolives
X
View Profile
View Bullboard History
Post by
kuatolives
on Mar 22, 2017 3:03pm
PPI May Cause Kidney Damage
Another risk: https://www.cbc.ca/news/health/heartburn-drugs-kidney-damage-1.3994789
(0)
•••
GoldenDilemma
X
View Profile
View Bullboard History
Comment by
GoldenDilemma
on Mar 21, 2017 11:51am
RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Picks like ARZ come around very rarely
Please point me in the direction of where I said that...? ARLZ has a lot more to do with earnings. In fact, based on earnings, they did well in the past Q. Doesn't matter, though.
(15)
•••
Systemtogo
X
View Profile
View Bullboard History
Comment by
Systemtogo
on Mar 21, 2017 11:50am
RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Picks like ARZ come around very rarely
So you buy your stocks based on earnings? Good luck with that. I always go against the sheep.
(0)
•••
GoldenDilemma
X
View Profile
View Bullboard History
Comment by
GoldenDilemma
on Mar 21, 2017 11:31am
RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Picks like ARZ come around very rarely
Sorry, should have clarified, the former (ARLZ), is specialty pharma. A well loved entity within the bio sector, especially if they take on debt to sell drugs (and, even more love if those drugs face
...more
(0)
•••
GoldenDilemma
X
View Profile
View Bullboard History
Comment by
GoldenDilemma
on Mar 21, 2017 11:29am
RE:RE:RE:RE:RE:RE:RE:RE:RE:Picks like ARZ come around very rarely
No comparison between ARLZ and AUP. The latter does R&D. The former has debt and a drug portfolio shorts deem worthless. But, again, fundamentals don't matter, right? ARLZ market cap
...more
(15)
•••
Systemtogo
X
View Profile
View Bullboard History
Post by
Systemtogo
on Mar 21, 2017 11:29am
Yosprala prospects
I think this drug is way undervalued. Think of how many elderly people there are that need aspirin and have acid reflux. It has brilliant mass market appeal. A good management team should be able to
...more
(15)
•••
Systemtogo
X
View Profile
View Bullboard History
Comment by
Systemtogo
on Mar 21, 2017 11:01am
RE:RE:RE:RE:RE:RE:RE:RE:Picks like ARZ come around very rarely
Management weren't buying all the way. You can refer to the following chart to see when they bought. I'm not basing my philosophy on ARZ, I'm basing on every pick I see that follows this
...more
(15)
•••
Systemtogo
X
View Profile
View Bullboard History
Comment by
Systemtogo
on Mar 21, 2017 10:53am
RE:RE:RE:RE:RE:RE:RE:Picks like ARZ come around very rarely
For someone who misunderstands it's unbelievable how many times I'm right. It's actually the only system worth a damm in trading.
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
How a truck transportation and logistics company leverages acquisitions and technology
High-grade gold potential in the world’s best mining jurisdiction
Undervalued Oil & Gas Play Readies for Strong H2 2024 with Canadian and US Assets